^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
favezelimab/pembrolizumab (MK-4280A)
i
Other names: MK-4280A, MK-4280/MK-3475, MK4280A, MK 4280A
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD)
Drug class:
PD1 inhibitor, LAG-3 inhibitor
Related drugs:
13d
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
P2, N=296, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
2ms
KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
P1/2, N=146, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=90 --> 146
Trial completion • Enrollment change
|
Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
2ms
KEYFORM-008: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (clinicaltrials.gov)
P2, N=203, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jan 2026 --> Sep 2025
Trial primary completion date
|
gemcitabine • favezelimab/pembrolizumab (MK-4280A)
2ms
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (clinicaltrials.gov)
P2, N=320, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2030 --> Oct 2025 | Trial primary completion date: Aug 2026 --> Oct 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
3ms
KEYMAKER-U02 Substudy 02B: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (clinicaltrials.gov)
P1/2, N=315, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2030 --> Apr 2026 | Trial primary completion date: Apr 2030 --> Apr 2026
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • vibostolimab (MK-7684) • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A)
3ms
KEYMAKER-U02 Substudy 02C: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) (clinicaltrials.gov)
P1/2, N=90, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2030 --> Oct 2025 | Trial primary completion date: Apr 2030 --> Oct 2025
Trial completion date • Trial primary completion date
|
Vesanoid (tretinoin) • vibostolimab (MK-7684) • Cavatak (gebasaxturev) • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
5ms
KEYMAKER-U02 Substudy 02B: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (clinicaltrials.gov)
P1/2, N=315, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • vibostolimab (MK-7684) • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A)
5ms
KeyImPaCT: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (clinicaltrials.gov)
P2, N=245, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> Jun 2025 | Trial primary completion date: Nov 2025 --> Jun 2025
Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK rearrangement
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab (MK-4280) • quavonlimab (MK-1308) • favezelimab/pembrolizumab (MK-4280A)
6ms
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (clinicaltrials.gov)
P2, N=302, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2027 --> Apr 2026 | Trial primary completion date: Jun 2026 --> May 2025
Trial completion date • Trial primary completion date • Mismatch repair • MSI-H • dMMR
|
MSI (Microsatellite instability)
|
MSI-H/dMMR • RAS wild-type
|
Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)
6ms
KEYFORM-008: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (clinicaltrials.gov)
P2, N=200, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2031 --> Jan 2026 | Trial primary completion date: May 2027 --> Jan 2026
Trial completion date • Trial primary completion date
|
gemcitabine • favezelimab/pembrolizumab (MK-4280A)
7ms
KEYMAKER-U03B: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) (clinicaltrials.gov)
P1/2, N=370, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> May 2026
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A)
8ms
KEYMAKER-U06 substudy 06A: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (clinicaltrials.gov)
P1/2, N=120, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2026 --> Nov 2025 | Trial primary completion date: Mar 2025 --> Nov 2025
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
Share via
